Agenus Inc Stock

$15.60+0.21 (+1.36%)
Updated Jul 12, 2024
AGEN Price
Fair Value Price
Market Cap
52 Week Low
52 Week High
Dividend Yield
Gross Margin
Operating Margin
Profit Margin
Debt to Equity
Operating Cash Flow
Next Earnings
Aug 6, 2024
Next Dividend

AGEN Overview

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AGEN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AGEN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AGEN is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
AGEN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more AGEN due diligence checks available for Premium users.

Be the first to know about important AGEN news, forecast changes, insider trades & much more!



AGEN fair value

Fair Value of AGEN stock based on Discounted Cash Flow (DCF)
Fair Value
Undervalued by
AGEN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AGEN price to earnings (PE)

For valuing profitable companies with steady earnings

AGEN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

AGEN's financial health

Profit margin

Net Income
Profit Margin
AGEN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AGEN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Debt to equity
AGEN's short-term liabilities ($256.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AGEN's long-term liabilities ($190.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AGEN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AGEN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

AGEN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AGEN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B

Agenus Stock FAQ

What is Agenus's quote symbol?

(NASDAQ: AGEN) Agenus trades on the NASDAQ under the ticker symbol AGEN. Agenus stock quotes can also be displayed as NASDAQ: AGEN.

If you're new to stock investing, here's how to buy Agenus stock.

What is the 52 week high and low for Agenus (NASDAQ: AGEN)?

(NASDAQ: AGEN) Agenus's 52-week high was $36.80, and its 52-week low was $4.78. It is currently -57.61% from its 52-week high and 226.7% from its 52-week low.

How much is Agenus stock worth today?

(NASDAQ: AGEN) Agenus currently has 20,999,261 outstanding shares. With Agenus stock trading at $15.60 per share, the total value of Agenus stock (market capitalization) is $327.59M.

Agenus stock was originally listed at a price of $5,550.00 in Feb 8, 2000. If you had invested in Agenus stock at $5,550.00, your return over the last 24 years would have been -99.72%, for an annualized return of -21.71% (not including any dividends or dividend reinvestments).

How much is Agenus's stock price per share?

(NASDAQ: AGEN) Agenus stock price per share is $15.60 today (as of Jul 12, 2024).

What is Agenus's Market Cap?

(NASDAQ: AGEN) Agenus's market cap is $327.59M, as of Jul 14, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Agenus's market cap is calculated by multiplying AGEN's current stock price of $15.60 by AGEN's total outstanding shares of 20,999,261.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.